3-phenyl-N-[4-(pyridin-4-ylmethyl)phenyl]propanamide

NDJ18 is a potent and selective SIRT2 inhibitor which validated the in silico protocol and opened up the possibility for generalization and broadening of its application. The anticancer effects of the most potent compound NDJ18 were examined on the triple-negative breast cancer cell line. Results indicated that NDJ18 represents a promising structure suitable for further evaluation.